Silibinin, a potential fasting mimetic, inhibits hepatocellular carcinoma by triggering extrinsic apoptosis

Abstract

Fasting, without inducing malnutrition, has been shown to have various beneficial effects, including the inhibition of tumor initiation and progression. However, prolonged fasting poses challenges for many cancer patients, particularly those in intermediate and terminal stages. Thus, there is an urgent need for the development of fasting mimetics which harness the protective effects of fasting but more suitable for patients. In this study, we first highlighted the pivotal role of silibinin in AMP-activated protein kinase (AMPK) pathway and may serve, as a potential fasting mimetic via screening hepatoprotective drugs. Further metabolic analysis showed that silibinin inhibited the adenosine triphosphate (ATP) levels, glucose uptake and diminished glycolysis process, which further confirmed that silibinin served as a fasting mimetic. In addition, fasting synergized with silibinin, or used independently, to suppress the growth of hepatocellular carcinoma (HCC) in vivo. Mechanistically, silibinin upregulated death receptor 5 (DR5) through AMPK activation, and thus promoting extrinsic apoptosis and inhibiting HCC growth both in vitro and in vivo. Inhibition of AMPK using small interfering RNA (siRNA) or compound C, an AMPK inhibitor, significantly attenuated the upregulation of DR5 and the apoptotic response induced by silibinin. These findings suggest that silibinin holds promise as a fasting mimetic and may serve as an adjuvant drug for HCC treatment.

Keywords

AMPK / apoptosis / fasting mimetic / hepatocellular carcinoma / silibinin

References

[1] Mcglynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(1):4-13. Suppl.

[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.

[3] Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer. 2020;147:317-330.

[4] Khan AA, Liu ZK, Xu X. Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2021;20:511-520.

[5] Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.

[6] Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71:1851-1864.

[7] Colman RJ, Beasley TM, Kemnitz JW, et al. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat Commun. 2014:5.

[8] Fontana L, Partridge L, Longo VD. Extending healthy life span–from yeast to humans. Science. 2010;328:321-326.

[9] Fontana L, Partridge L. Promoting health and longevity through diet: from model organisms to humans. Cell. 2015;161:106-118.

[10] Longo VD. Mattson M P Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014;19:181-192.

[11] Jordan S, Tung N, Casanova-Acebes M, et al. Dietary intake regulates the circulating inflammatory monocyte pool. Cell. 2019;178:1102-1114. e17.

[12] Di Biase S, Lee C, Brandhorst S, et al. Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity. Cancer Cell. 2016;30:136-146.

[13] Allen BD, Liao CY, Shu J, et al. Hyperadrenocorticism of calorie restriction contributes to its anti-inflammatory action in mice. Aging Cell. 2019;18:e12944.

[14] Okada T, Otsubo T, Hagiwara T, et al. Intermittent fasting prompted recovery from dextran sulfate sodium-induced colitis in mice. J Clin Biochem Nutr. 2017;61:100-107.

[15] Meynet O, Ricci JE. Caloric restriction and cancer: molecular mechanisms and clinical implications. Trends Mol Med. 2014;20:419-427.

[16] Brandhorst S, Longo V. Fasting and caloric restriction in cancer prevention and treatment. Recent Results Cancer Res. 2016;207:241-266.

[17] Curry NL, Mino-Kenudson M, Oliver TG, et al. Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. Cancer Discov. 2013;3:908-921.

[18] Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B, et al. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci USA. 1994;91:9995-9999.

[19] Alidadi M, Banach M, Guest PC, et al. The effect of caloric restriction and fasting on cancer. Semin Cancer Biol. 2021;73:30-44.

[20] Clifton KK, Ma CX, Fontana L, Peterson L. Intermittent fasting in the prevention and treatment of cancer. CA Cancer J Clin. 2021;71:527-546.

[21] Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature. 2009;458:725-731.

[22] Pietrocola F, Pol J, Vacchelli E, et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell. 2016;30:147-160.

[23] Lee C, Raffaghello L, Brandhorst S, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4:124ra27.

[24] Krstic J, Reinisch I, Schindlmaier K, et al. Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism. Sci Adv. 2022;8:eabh2635.

[25] Lu Z, Xie J, Wu G, et al. Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. Nat Med. 2017;23:79-90.

[26] Caffa I, Spagnolo V, Vernieri C, et al. Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature. 2020;583:620-624.

[27] Cavric G, Ilic D, Njers K, Prkacin I, Hamp DB. Native valve endocarditis caused by methicillin-resistant staphylococcus epidermidis in a patient with advanced liver cirrhosis. Acta Clin Croat. 2015;54:531-535.

[28] Levesque S, Le Naour J, Pietrocola F, et al. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. Oncoimmunology. 2019;8:e1657375.

[29] Madeo F, Carmona-Gutierrez D, Hofer SJ, Kroemer G. Caloric restriction mimetics against age-associated disease: targets, mechanisms, and therapeutic potential. Cell Metab. 2019;29:592-610.

[30] Nencioni A, Caffa I, Cortellino S, Longo VD. Fasting and cancer: molecular mechanisms and clinical application. Nat Rev Cancer. 2018;18:707-719.

[31] Hsu CC, Peng D, Cai Z, Lin HK. AMPK signaling and its targeting in cancer progression and treatment. Semin Cancer Biol. 2022;85:52-68.

[32] Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19:121-135.

[33] Cantó C, Auwerx J. Calorie restriction: is AMPK a key sensor and effector? Physiology. 2011;26:214-224.

[34] Garcia D, Shaw RJ. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell. 2017;66:789-800.

[35] Carling D. AMPK signalling in health and disease. Curr Opin Cell Biol. 2017;45:31-37.

[36] Zhang CS, Li M, Wang Y, et al. The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. Nat Metab. 2022;4:1369-1401.

[37] Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.

[38] Barzilai N, Crandall JP, Kritchevsky SB, Espeland M. A metformin as a tool to target aging. Cell Metab. 2016;23:1060-1065.

[39] Pietrocola F, Castoldi F, Markaki M, et al. Aspirin recapitulates features of caloric restriction. Cell Rep. 2018;22:2395-2407.

[40] Pietrocola F, Castoldi F, Maiuri MC, Kroemer G. Aspirin-another caloric-restriction mimetic. Autophagy. 2018;14:1162-1163.

[41] Liu J, Chen D, Liu P, et al. Discovery, synthesis, and structure–activity relationships of 20(S)-protopanaxadiol (PPD) derivatives as a novel class of AMPKα2β1γ1 activators. Eur J Med Chem. 2014;79:340-349.

[42] Li W, Wang Y, Zhou X, et al. The anti-tumor efficacy of 20(S)-protopanaxadiol, an active metabolite of ginseng, according to fasting on hepatocellular carcinoma. J Ginseng Res. 2022;46:167-174.

[43] Price Nathan L, Gomes Ana P, Ling Alvin JY, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15:675-690.

[44] Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008;8:157-168.

[45] Davinelli S, De Stefani D, De Vivo I, Scapagnini G. Polyphenols as caloric restriction mimetics regulating mitochondrial biogenesis and mitophagy. Trends Endocrinol Metab. 2020;31:536-550.

[46] Jiang Y, Yang X, Dong C, et al. Five-day water-only fasting decreased metabolic-syndrome risk factors and increased anti-aging biomarkers without toxicity in a clinical trial of normal-weight individuals. Clin Transl Med. 2021;11:e502.

[47] Hanahan D, Weinberg R. A hallmarks of cancer: the next generation. Cell. 2011;144:646-674.

[48] Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27-47.

[49] Warburg OH. The classic: the chemical constitution of respiration ferment. Clin Orthop Relat Res. 2010;468:2833-2839.

[50] Weng ML, Chen WK, Chen XY, et al. Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1alpha pathway suppression. Nat Commun. 2020;11:1869.

[51] Jiang Y, Tang Z, Zhu X, et al. Non-invasive omics analysis delineates molecular changes in water-only fasting and its sex-discriminating features in metabolic syndrome patients. MedComm. 2023;4:e393.

[52] Hou S, Zhang T, Li Y, Guo F, Jin X. Glycyrrhizic acid prevents diabetic nephropathy by activating AMPK/SIRT1/PGC-1alpha signaling in db/db mice. J Diabetes Res. 2017;2017:2865912.

[53] Zhang X, Yang H, Yue S, et al. The mTOR inhibition in concurrence with ERK1/2 activation is involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma. Cancer Med. 2017;6:1941-1951.

[54] Khan I, Preeti K, Kumar R, Khatri DK, Singh SB. Activation of SIRT1 by silibinin improved mitochondrial health and alleviated the oxidative damage in experimental diabetic neuropathy and high glucose-mediated neurotoxicity. Arch Physiol Biochem. 2022:1-17.

[55] Wang C, He C, Lu S, et al. Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF. Cell Death Disease. 2020;11:630.

[56] Pu Z, Zhang W, Wang M, et al. Schisandrin B attenuates colitis-associated colorectal cancer through SIRT1 linked SMURF2 signaling. Am J Chin Med. 2021;49:1773-1789.

[57] Zhu L, Wang Y, Lv W, et al. Schizandrin A can inhibit non‑small cell lung cancer cell proliferation by inducing cell cycle arrest, apoptosis and autophagy. Int J Mol Med. 2021;48:214.

[58] Tang MC, Cheng L, Qiu L, et al. Efficacy of tiopronin in treatment of severe non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2014;18:160-164.

[59] Michele Malaguarnera MM. Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. Am J Transl Res. 2015;7(11):2510-2518.

[60] Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011;17:2288-2301.

[61] Soleimani V, Delghandi PS, Moallem SA, Karimi G. Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review. Phytother Res. 2019;33:1627-1638.

[62] Brandon-Warner E, Eheim AL, Foureau DM, et al. Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice. Cancer Lett. 2012;326:88-95.

[63] Loguercio C, Andreone P, Brisc C, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med. 2012;52:1658-1665.

[64] Xu R, Qiu S, Zhang J, et al. Silibinin Schiff base derivatives counteract CCl(4)-induced acute liver injury by enhancing anti-inflammatory and antiapoptotic bioactivities. Drug Des Dev Ther. 2022;16:1441-1456.

[65] Fernandes G, Yunis EJ, Good R. A suppression of adenocarcinoma by the immunological consequences of calorie restriction. Nature. 1976;263:504-507.

[66] Jee Sh OH, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in korean men and women. JAMA. 2005;293(2):194-202.

[67] Marinac CR, Nelson SH, Breen CI, et al. Prolonged nightly fasting and breast cancer prognosis. JAMA Oncol. 2016;2:1049-1055.

[68] Bauersfeld SP, Kessler CS, Wischnewsky M, et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer. 2018;18:476.

[69] Mohamed SY, Emara MH, Hussien HI, Elsadek HM. Changes in portal blood flow and liver functions in cirrhotics during Ramadan fasting in the summer; a pilot study. Gastroenterol Hepatol Bed Bench. 2016;9:180-188.

[70] Elnadry MH, Nigm IA, Abdel Aziz IM, et al. Effect of Ramadan fasting on Muslim patients with chronic liver diseases. J Egypt Soc Parasitol. 2011;41:337-346.

[71] Ligorio F, Fuca G, Provenzano L, et al. Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: a sub-analysis of the NCT03340935 trial. Eur J Cancer. 2022;172:300-310.

[72] Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet. 1990;15:333-338.

[73] Weyhenmeyer R, Mascher H, Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol. 1992;30:134-138.

[74] Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15:1940-1949. e8.

[75] Siegel AB, Stebbing J. Milk thistle: early seeds of potential. Lancet Oncol. 2013;14:929-930.

[76] Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659-661.

[77] Li L, Zeng J, Gao Y, He D. Targeting silibinin in the antiproliferative pathway. Expert Opin Investig Drugs. 2010;19:243-255.

[78] Tuli HS, Mittal S, Aggarwal D, et al. Path of Silibinin from diet to medicine: a dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance. Semin Cancer Biol. 2021;73:196-218.

[79] Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int. 2013;2013:421821.

[80] Si L, Fu J, Liu W, et al. Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion. Mol Cell Biochem. 2020;463:189-201.

[81] Riebold M, Kozany C, Freiburger L, et al. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med. 2015;21:276-280.

[82] Verdura S, Cuyas E, Llorach-Pares L, et al. Silibinin is a direct inhibitor of STAT3. Food Chem Toxicol. 2018;116:161-172.

[83] Zhao P, Sun X, Chaggan C, et al. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science. 2020;367:652-660.

[84] Wang C, He H, Liu G, et al. DT-13 induced apoptosis and promoted differentiation of acute myeloid leukemia cells by activating AMPK-KLF2 pathway. Pharmacol Res. 2020;158:104864.

[85] Madeo F, Pietrocola F, Eisenberg T, Kroemer G. Caloric restriction mimetics: towards a molecular definition. Nat Rev Drug Discov. 2014;13:727-740.

[86] Wei M, Brandhorst S, Shelehchi M, et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017;9(377):eaai8700.

[87] Ingram DK, Zhu M, Mamczarz J, et al. Calorie restriction mimetics: an emerging research field. Aging Cell. 2006;5:97-108.

[88] Ren G, Ma Y, Wang X, Zheng Z, Li G. Aspirin blocks AMPK/SIRT3-mediated glycolysis to inhibit NSCLC cell proliferation. Eur J Pharmacol. 2022;932:175208.

[89] Raina K, Agarwal C, Wadhwa R, Serkova NJ, Agarwal R. Energy deprivation by silibinin in colorectal cancer cells: a double-edged sword targeting both apoptotic and autophagic machineries. Autophagy. 2013;9:697-713.

[90] Garcia-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene. 2009;28:313-324.

[91] Chen X, Lin X, Li M. Comprehensive modulation of tumor progression and regression with periodic fasting and refeeding circles via boosting IGFBP-3 loops and NK responses. Endocrinology. 2012;153:4622-4632.

[92] Sun P, Wang H, He Z, et al. Fasting inhibits colorectal cancer growth by reducing M2 polarization of tumor-associated macrophages. Oncotarget. 2017;8:74649-74660.

RIGHTS & PERMISSIONS

2024 2024 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.